GO:0006953 acute-phase response: Genes and Research

The acute-phase response (GO:0006953) is a rapid, systemic inflammatory reaction that occurs within hours to days after infection, tissue injury or immunological challenge in homeothermic animals. It is characterized by dramatic changes in the plasma concentrations of a defined set of non-antibody proteins, collectively called acute-phase proteins, which are produced primarily by the liver under cytokine control. This response is evolutionarily conserved and serves to limit tissue damage, neutralize pathogens and restore homeostasis. Because acute-phase proteins such as C-reactive protein (CRP), serum amyloid A (SAA) and haptoglobin are easily measured in blood, the acute-phase response has become a cornerstone of both veterinary and human clinical diagnostics. Mechanistically, the acute-phase response is initiated when innate immune cells detect pathogen-associated or damage-associated molecular patterns and release pro-inflammatory cytokines, especially interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor (TNF). These cytokines act on hepatocytes through receptor-mediated signaling cascades, including the JAK/STAT3 and NF-kB pathways, to reprogram gene expression toward acute-phase protein synthesis. The resulting surge in positive acute-phase proteins is accompanied by a decrease in negative acute-phase proteins such as albumin and transferrin. This coordinated shift in the plasma proteome is a hallmark of the acute inflammatory state. For researchers, GO:0006953 provides a structured framework to study the molecular links between infection, inflammation and metabolism. The term is widely used in transcriptomic, proteomic and clinical studies of sepsis, trauma, burns and parasitic diseases. Moreover, because the acute-phase response intersects with oxidative stress, nutritional status and immune cell function, it is a rich area for CRISPR-based functional genomics. Understanding its regulation and effector proteins can reveal new biomarkers and therapeutic targets for inflammatory disease.

According to the Gene Ontology, GO:0006953 acute-phase response is an acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals. In other words, it is the physiological process by which the body rapidly elevates a specific set of plasma proteins, such as CRP, SAA and fibrinogen, as part of the early innate immune reaction to harm. This definition distinguishes the acute-phase response from antibody-mediated adaptive immunity and from chronic inflammatory states.

The acute-phase response is important because it represents one of the earliest and most conserved systemic reactions to infection and tissue damage, and its protein products are among the most widely used clinical biomarkers in human and veterinary medicine. Dysregulation of this response is associated with worse outcomes in conditions ranging from necrotizing fasciitis and severe burns to parasitic infections and coccidiosis. Studying GO:0006953 therefore provides insight into fundamental innate immunity, inflammation resolution and the pathophysiology of acute and critical illness.

The following genes encode key cytokines, signaling molecules and acute-phase proteins that define GO:0006953 acute-phase response.

The acute-phase response is tightly regulated at multiple levels. Cytokine signaling through JAK/STAT3 and NF-kB is controlled by negative feedback regulators such as SOCS3, which dampens IL-6 signaling to prevent excessive inflammation. Glucocorticoids and other hormones modulate the magnitude of acute-phase protein induction, and nutritional status can influence substrate availability for protein synthesis. In chronic inflammatory states, persistent cytokine stimulation can lead to sustained acute-phase protein elevation, which is associated with tissue damage and poor outcomes. Understanding these regulatory layers is essential for designing interventions that preserve host defense while limiting collateral injury.

Necrotizing fasciitis is a rapidly progressive soft-tissue infection that triggers a massive acute-phase response, often with marked elevation of CRP and other acute-phase proteins. In children with musculoskeletal infection, the acute-phase response can be a double-edged sword, contributing to both pathogen clearance and tissue damage. These conditions illustrate how an exaggerated or dysregulated acute-phase response can worsen clinical outcomes and complicate diagnosis.

Critically ill elderly burn patients exhibit profound and prolonged acute-phase responses that correlate with mortality and complications. The magnitude and duration of acute-phase protein elevation in these patients reflect the severity of injury and the presence of secondary infections. Monitoring acute-phase proteins in burn and intensive care settings can guide clinical decision-making and prognostication.

Parasitic blood diseases of ruminants and coccidiosis in domestic animals are accompanied by acute-phase responses that can be used to assess disease severity and treatment response. In coccidiosis, the acute-phase response is closely linked to oxidative stress, and acute-phase proteins such as haptoglobin and SAA are elevated. These veterinary examples highlight the conserved nature of GO:0006953 across homeothermic species.

RNA sequencing (RNA-seq) of hepatocytes or liver tissue before and after cytokine stimulation can identify the full set of genes whose expression changes during the acute-phase response. This approach reveals both positive and negative acute-phase genes and their regulatory networks. Comparative RNA-seq across species can highlight conserved and species-specific acute-phase programs.

Mass spectrometry-based proteomics and immunoassays such as ELISA are used to quantify acute-phase proteins in plasma or cell culture supernatants. These methods provide direct evidence of protein concentration changes that define GO:0006953. Multiplex immunoassays allow simultaneous measurement of multiple acute-phase proteins for biomarker discovery.

Genome-wide CRISPR knockout or activation screens in hepatocyte cell lines can identify genes that regulate acute-phase protein expression. Such screens can uncover novel signaling components, transcription factors and feedback regulators. Hits from these screens can be validated by targeted knockout or overexpression.

Animal models of infection, burn injury or parasitic disease are used to study the acute-phase response in a physiological context. These models allow measurement of acute-phase proteins in blood and correlation with clinical outcomes. They also enable testing of therapeutic interventions targeting the acute-phase response.

Researchers studying acute-phase response-related genes often need to determine whether a candidate gene is causally involved in cytokine signaling, acute-phase protein synthesis or inflammatory pathology. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models for functional studies of GO:0006953.

GO:0006953 acute-phase response is a fundamental biological process that coordinates systemic inflammation through cytokine-driven changes in plasma protein synthesis. Its clinical importance spans infectious disease, trauma, burns and veterinary medicine, where acute-phase proteins serve as essential biomarkers. CRISPR-based functional genomics offers powerful tools to dissect the regulatory networks and effector functions of the acute-phase response, paving the way for new diagnostics and therapies.